CareDx Q2 2026: Growth Harvests a One-Time Gain, Budgets for the Next Stage

Overview

CareDx, Inc. (Nasdaq: CDNA) delivered its second-quarter 2026 update with a tidy revenue beat and a notable one-off contributor: a $113 million gain on the sale of the Lab Products business. The quarter’s headline figures show a revenue of $132 million, up 52% year over year, underscoring the company’s continued strength in Testing Services and a broader tilt toward higher‑value segments in transplant diagnostics and companion offerings.

The press release emphasizes the GAAP bottom line, reporting GAAP net income of $111 million driven by the sale, in contrast to a GAAP net loss in the prior-year quarter. Non-GAAP operating income excludes the sale gain, highlighting the common investor question: how much of the current income is structural growth versus one-time accounting noise? The company reiterates momentum across its core franchises and notes a notable increase in per‑test economics that helps frame the longer-term outlook.

Financial Highlights

• Revenue of $132 million, a 52% year-over-year increase.
• Testing Services revenue of $100 million, up 61% YoY; volume ~58,000 tests, up 17%.
• Patient and Digital Solutions revenue of $19 million; Lab Product revenue of $13 million.
• Average revenue per test about $1,720, with $16 million in prior-period revenue recognized.
• GAAP net income $111 million, vs. GAAP net loss in Q2 2025; aided by the Lab Products sale gain.
• Adjusted EBITDA $25 million, up from $5 million in the prior-year quarter.
• Cash flow from operations $31 million.

Divestitures, Acquisitions, and Portfolio Strategy

A key strategic move is the divestiture of Lab Products to Eurobio Scientific, matched with the acquisition of Naveris, a combination the company frames as strengthening CareDx’s position as a differentiated precision molecular diagnostics company. The timing creates a leaner core focused on transplant, specialty oncology, and cell therapy—areas where the firm aims to convert testing activity into durable revenue streams.

Management flags continued progress on the AlloSure and AlloMap franchises, as well as the broader pipeline, with data and publications supporting the company’s molecular testing portfolio. These moves matter for investors buffering against a single‑line story and looking for operational leverage as the company exits one line of business to invest in higher‑growth areas.

Outlook and Industry Context

CareDx raised its 2026 guidance to a revenue forecast of $490 million to $500 million and an AEBITDA range of $66 million to $78 million. The guidance implies confidence in ongoing demand for Testing Services and the continued monetization of newer offerings, even as the company consolidates its portfolio post‑divestiture.

The quarter also notes regulatory and reimbursement dynamics, including CMS finalization of Medicare coverage for AlloSure and AlloMap, which could improve patient access and test utilization. For peers in the transplant and molecular diagnostics space, the message is clear: targeted, coverage-backed offerings paired with disciplined portfolio management can shift both growth trajectories and capital allocation discipline.

Analysis: What It Means for CareDx and Sector Peers

The standout feature is not just the top-line growth, but the structure of that growth. A large portion of the quarterly improvement comes from high‑multiples testing services, with a per‑test price that hints at durable value creation. The Lab Products divestiture removes a lower‑growth, more asset‑heavy business line from the equation, allowing management to reallocate capital toward faster‑rate growth areas and higher‑margin opportunities.

For investors, the EPS angle will hinge on whether the Q2 GAAP earnings strength persists absent the sale gain and how well the company sustains its testing volumes amid evolving reimbursement landscapes. There is room for a potential earnings surprise scenario if the growth in testing drives continued margin expansion and the company maintains or modestly raises the revenue forecast through year‑end.

In terms of sector dynamics, CareDx’s progress underscores a broader trend: convergence of transplant diagnostics, precision oncology, and cell therapy testing into integrated care pathways. The acquisition of Naveris signals a strategic push into next‑generation capabilities, while Medicare coverage enhancements reduce the friction of adoption for AlloSure/AlloMap. Peers may respond with accelerations in pipeline milestones, more aggressive cost controls, or divestitures of less strategic assets to focus on high‑growth adjacencies.

Final Thoughts

CareDx’s Q2 narrative blends a meaningful revenue leap with a one‑time accounting windfall, and a refreshed plan that prioritizes growth engines over portfolio breadth. The question for the stock and for peers becomes: can the core revenue storyline sustain without the Lab Products tailwind? If the answer trends yes, supported by AlloSure/AlloMap reimbursement tailwinds and a successful Naveris integration, the company could offer a blueprint for how specialized diagnostics firms navigate the post‑divestiture phase.

As always, investors will scrutinize the EPS trajectory, scan for any earnings surprise relative to EPS consensus, and watch the revenue forecast for signs of durable, non‑one‑off growth. In the meantime, CareDx continues to transplant its growth story from concept to clinical reality, with a few more tests and a little less ballast in the ballast‑heavy Lab Products division.